N-benzyl oxycarbonyl-γ-aminobutyric acid | 911319-76-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-benzyl oxycarbonyl-γ-aminobutyric acid
• 英文别名: 2-(benzylamino)glutamic acid；N-(phenylmethyl)glutamic acid；N-benzylglutamic acid；benzylglutamic acid；N-Benzyl-glutamic acid；2-(benzylamino)pentanedioic Acid
• CAS: 911319-76-1
• 化学式: C₁₂H₁₅NO₄
• mdl: MFCD03414578
• 分子量: 237.255
• InChiKey: IHSNQUNHINYDDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-benzyl oxycarbonyl-γ-aminobutyric acid 以 水 为溶剂， 生成 (S)-1-苄基-5-氧代吡咯烷-2-羧酸
  参考文献：
  名称：

  Angiotensin II antagonist intermediates

  摘要：

  该发明提供了新颖的杂环衍生物，它们的药物配方以及它们用于拮抗哺乳动物中的血管紧张素II受体的用途。

  公开号：

  US05556981A1
• 作为产物：
  描述：

  DL-谷氨酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 2.17h， 生成 N-benzyl oxycarbonyl-γ-aminobutyric acid
  参考文献：
  名称：

  A Vitamin E Derivative as a Novel, Extremely Advantageous Amino-Protecting Group

  摘要：

  DOI：

  10.1021/jo00130a002

文献信息

• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• [EN] RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING<br/>[FR] ACIDES AMINÉS RADIO-MARQUÉS POUR IMAGERIE DE DIAGNOSTIC
  申请人：BAYER PHARMA AG

  公开号：WO2012150220A1

  公开（公告）日：2012-11-08

  This invention relates to novel compounds suitable for labeling by 18F and to the corresponding 18F labeled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).

  这项发明涉及适合用18F标记的新化合物，以及相应的18F标记化合物本身，其19F-氟化类似物及其作为参考标准的用途，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及用于正电子发射断层扫描（PET）的这种化合物、组合物或试剂盒的用途。
• Angiotensin II antagonists
  申请人：Eli Lilly and Company

  公开号：US05612360A1

  公开（公告）日：1997-03-18

  This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

  这项发明提供了新颖的杂环衍生物，它们的制药配方，以及它们用于拮抗哺乳动物中的血管紧张素II受体的用途。
• [EN] POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS<br/>[FR] EXCIPIENTS POLYMÈRES POUR DES APPLICATIONS D'ADMINISTRATION DE MÉDICAMENT
  申请人：TYNDALL FORMULATION SERVICES LLC

  公开号：WO2021141603A1

  公开（公告）日：2021-07-15

  The present disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block and uses thereof.

  本公开涉及聚合物化学领域，更具体地涉及包含聚（肌氨酸）块和D，L混合聚（氨基酸）块的多嵌段共聚物及其用途。
• Active agent delivery systems and methods for protecting and administering active agents
  申请人：New River Pharmaceuticals Inc.

  公开号：US20040063628A1

  公开（公告）日：2004-04-01

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽的组成部分，与活性物质共价连接的组合物和用于给予共轭活性物质组合物的方法。